Summary A tumour model consisting of the highly metastatic mammary 13762 parental line, the nonmetastatic and 6-thioguanine-resistant (TgR) variant line, and two TgR revertant lines (TgRrev, TgRrevM) that were occasionally metastatic, were used to determine whether the relase of N-acetylneuraminic acid (NANA) was related to tumour metastasis. For comparative purposes, the occasionally metastatic R3230AC and the nonmetastatic DMBA8 tumour lines were studied. The NANA was considered to be in bound form, because acid hydrolysis was required to release it for high-pressure liquid chromatographic analyses. Sera of animals bearing the 13762 and R3230AC tumours had high levels of bound NANA. No differences were found in serum NANA levels in animals bearing metastatic or non-metastatic R3230AC tumours. Low levels of bound NANA were found in animals bearing the other tumour lines regardless of whether metastasis occurred or not. The experiments in vitro substantiated the in vivo findings. The phenotypic expression of bound NANA shedding did not correlate well with metastatic potential of the mammary tumour line. Our analyses suggest that this phenotypic marker cannot be used as a reliable indicator of metastasis.
The shedding of cell-surface components may play an important role in the process of metastasis. In both animals and human studies, the level of shedding is considered to be related to metastatic ability (Bernacki & Kim, 1977; Black, 1980; Dennis et al., 1981) . The cell components shed can consist of proteases, adhesion molecules, and antigens which may impair the immune reponse (Black, 1980; Hynes, 1976) . Tumour cells also seem to have an increased content of sialic acid on cell surface membranes (Alhadeff & Holzinger, 1982; Black, 1980; Huggins et al., 1980) and such bound sialic acid has often been detected in the serum of tumour-bearing hosts and in spent cell-culture medium (Bemacki & Kim, 1977; Grimm et al., 1976; Kloppel et al., 1977; Silver et al., 1979) . From these studies it is suggested that shedding of bound sialic acid may relate to metastasis. However, some of the difficulties in validating the shedding hypothesis lies in the fact that (a) in most studies, the in vitro and in vivo experiments have not been performed simultaneously, (b) the cells employed, though exhibiting varying metastatic potential, generally have different origins and (c) the tumour cell lines are not from the same syngeneic host. In this report we have incorporated the above considerations to determine whether NANA shedding can be used as a phenotypic marker for tumour metastasis.
Correspondence: D.B.S. Hoon Received 22 October 1984; and in revised form 14 February 1985. B We recently reported the isolation of a 6-thioguanine-resistant cell line from the 13762 mammary adenocarcinoma that is not only much less tumourigenic but also unable to metastasize in normal rats (Ramshaw et al., 1982) . Also, we detailed the capacity of other rat mammary adenocarcinomas to spontaneously metastasize (Hoon et al., 1983) . The availability of these tumour cell lines, which vary in their metastatic ability, afforded us the opportunity to study the cellsurface shedding of bound N-acetylneuraminic acid. HPLC analysis was used to quantitate the levels of bound NANA released in specimen hydrolysates. In this report, we show both in vitro and in vivo that shedding of bound NANA did not correlate to the metastatic potential of the mammary tumour lines.
Materials and methods

Animals and tumour cell lines
The mammary tumour cell lines used were the 13762, DMBA8, R3230AC, TgR, TgRrev and TgRrevM, all syngeneic to the F344 rat. The tumours were grown and handled as previously reported (Hoon et al., 1983; . The 13762 is a highly metastatic tumour (100%), whereas the R3230AC tumour metastasizes in 45 -100% of the animals. The DMBA8 always grows as a primary tumour but does not metastasize. A 6-thioguanine(TgR)-resistant variant was obtained from the 13762 cell line, which was found to be poorly tumourigenic and non-metastatic (Ramshaw et al., 1982) . From the TgR variant, two more cell lines were derived, the TgRrev and TgRrevM, which were metastatic and more tumourigenic than the TgR line itself. The differences between the TgRrevM and TgRrev are minor, the former is more metastatic in the lung tumour colony assay (Ramshaw et al., 1982) . These metastatic derivatives metastasized in 10 -60% of the animals. The metastatic ability of these tumour lines was assessed by injecting the cells into the hind footpad and assessing lymphatic metastasis in the draining regional lymph nodes at regular intervals (Hoon et al., 1983) .
Serum specimens Rats were bled from the tail vein prior to tumour cell injection (pre-bleed sera) and periodically thereafter (Hoon et al., 1983 (Silver et al., 1979 ), compared to the colorimetric procedures (Tuppy & Gottschalk, 1972) . The NANA was hydrolyzed from its bound form by acid treatment as follows: the sample was diluted 1:20 (v/v) with 0.1 M sulphuric acid, while the culture medium sample was diluted 1:10 with 1 M sulphuric acid. The diluted samples were then heated at 80°C for 1 h. Hydrolysates were then cooled for 15min in a 20°C water bath, and further diluted 1:1 (v/v) with distilled water. This minimized the interference of the acid peak during HPLC analyses on a model 332 gradient system fitted with model 11OA pumps (Beckman, Berkeley, CA) and Aminex HPX-87 cation exchange column (300x7.8mm, Bio-Rad Lab., Richmond, CA). The NANA in the sample was eluted by a mobile phase of 0.006 M sulphuric acid at a flow rate of 0.65mlmin-1 and pressure of 7 +106Nm 2. The eluant was monitored at 206nm by a model 100-40 spectrophotometer (Hitachi, Tokyo, Japan) fitted with a 5 M1 flow cell and an Altex integrator recorder (Shimadzu Corp., Kyoto, Japan). Samples at 20 1 were injected into the sampling port via a Hamilton syringe, preset running time for each assay was 15min. Each sample was examined at least twice, and interassay variations where <5%.
The amount of NANA in samples was determined by comparing the area of the peak with a standard curve of hydrolyzed NANA (0.15 to 5pmolml-1) established by the same HPLC procedure. The lowest concentration that could be detected by this system was 10nmolml-1. The eulted NANA had a retention time of 7.5 min, while the forerunning acid peak was at 6.0 min; when the tumour serum hydrolysates were assayed, only an acid and a NANA peak were observed. When the NANA standard solution was mixed with tumour serum hydrolysate, there was only one peak at the NANA retention time. On running the tumour serum hydrolysate, culture medium hydrolysate, and standard NANA, in separate runs, the NANA peak retention times were identical. Appropriate concentrations of N-acetyl galactosamine (Sigma, St. Louis, MO) and Nacetyl-mannosamine (Sigma) were incorporated into the samples as internal standards. The retention times did not coincide with the peaks observed with the respective serum hydrolysates; they were at 8.9 and 11.1 min, respectively. Serum hydrolysates could be stored at 4°C for 48 h without any significant loss of NANA concentration. Pre-bleed specimens and the zero time point for culturemedium specimens for each assay were considered as baseline or background levels. The values obtained after this point were expressed in terms of increases over baseline levels. Normal control serum specimens taken at random diurnal periods for sexage-matched rats were 2.95 + 0.05 s.e. ,mol ml -1I Pre-bleed and post tumour injection serum specimens that were not hydrolyzed by acid had undetectable levels of free NANA. In culture specimens, the main source of background level of bound NANA was from the calf serum, which was 327+ 11.1 s.e.nmolmml.
Statistics
The Student t-test was used for statistical analysis. In the comparison of serum specimens, the maximum level of bound NANA obtained for each tumour-bearing animal was used.
Results
Animal studies All animals injected in the hind footpad with 106 or 5 x 106, 13762 cells developed large primary tumours (x= 7 mm diam.) and palpable lymph nodes by day 25. The 13762 tumour growth was rapid, and the size increased in a linear fashion. Concomitantly, the bound NANA in the sera of these tumour-bearing animals increased by Day 5 and started to plateau by Day 10 ( Figure IA ). These findings suggested that the increase of bound NANA in sera of 13762 tumour-bearing animals is related to the rapid growth and/or metastatic ability of the tumour. In comparison, the sera of TgR, TgRrev, and TgRrevM tumour-bearing animals ( Figure 1B ) were analyzed and found to contain -3-4 times less bound NANA than that in the 13762 tumour-bearing animals. The differences in NANA between 13762 and the other tumours studied were not considered to be due to tumour load, as most of the animals had developed comparable tumour masses at the termination of E E Z z z E a) co the experiment. Because TgR, TgRrev, and TgRrevM cells were poorly tumourigenic, it was necessary to inject 5 x 106 cells to produce tumours. In the TgR tumour-bearing animals, the growth of the primary tumour progressed in a linear fashion, and by Day 75, the tumour had reached a size of 11.0mm x diam., at which time the animals were sacrificed. However, palpable lymph node metastases were not detected in these animals, and careful histological examination of the draining lymph nodes also showed no evidence of micrometastasis. In contrast, 3 out of 5 animals injected with TgRrev cells had. palpable lymph node metastasis at the termination of the experiment. As for the TgRevM tumour-bearing animals, 2 of the 4 had palpable lymph node metastasis. Again, no micrometastases were detected on histological examination of non-palpable lymph nodes. Although tumour growth increased in a linear fishion in both the TgRrev and TgRrevM tumourbearing animals, the amount of NANA in the sera of these animals did not increase proportionally. No significant differences occurred in bound NANA levels of animals bearing metastatic TgRrev and TgRrevM tumours compared to those animals bearing non-metastatic tumours.
In R3230AC tumour-bearing animals, the levels of bound NANA in sera were low at the early stages of primary tumour growth ( Figure 2) ; however, after day 54 post tumour cell injection (106 cells) the levels increased as the growth of the primary tumours increased rapidly. The experiment was terminated on day 81 because of the size of the primary tumours (x= 19.0mm diam.). There were no significant differences in the levels of bound NANA Figure 2 Increased levels of bound NANA in sera of rats inoculated with R3230AC tumour cells. Rats were divided into 3 groups at the termination of the experiment; these groups are: rats (9) with no metastasis (0); rats (6) with micrometastasis (-); and rats (4) Cell culture studies To support the above in vivo studies, the tumour cell lines were examined for in vitro shedding using cell-culture conditions. Without acid hydrolysis, no NANA was detected in the spent culture medium of all cell lines tested. However, upon acid hydrolysis, the culture medium of the 13762 cells contained more bound NANA than the other tumour cells ( Figure 3A) . Also, the amount of bound NANA in the medium, presumably shed by 'Comparative ranking based on general bound NANA released in spent culture medium and levels in sera of tumour-breaing rats; comparison amongst the tumour lines studied. the 13762 cells, increased in a linear fashion.
Comparatively, the amount of bound NANA (above norm) in the media of TgR TgRrev, and TgRrevM tumour cells was low ( Figure 3A , Table  I ). In the R3230AC cultures, the amount of bound NANA increased steadily in linear fashion ( Figure  3B In this study, shedding of bound NANA by mammary tumour lines was investigated using both in vitro and in vivo conditions. We asked the question does shedding of bound NANA correlate to the metastatic potential of tumour cells? In these studies the sera of animals bearing the highly metastatic 13762 tumour contained greater amounts of bound NANA than the sera of animals bearing other tumours. The in vitro findings also supported the in vivo findings, in that the 13762 cells shed high levels of bound NANA into the culture medium. In comparison the serum levels of bound NANA in TgR tumour-bearing animals were low, similarly the TgR cells in culture released small amounts of bound NANA. These results did show that there was a difference in NANA shedding between metastatic and nonmetastatic tumour cells of the same origin. However the TgRrev and TgRrevM tumours which were found to be occasionally metastatic, had only low levels of bound NANA in sera and in spent culture medium. The metastatic TgR variants were expected to shed more bound NANA than the TgR variant. One reason for the low level of shedding by these metastatic variants is that like other tumours they contain a population of cells that are heterogeneous in their metastatic ability. In such a situation, the presence of effective metastatic potentials may be very low, as suggested by a recent study on experimental metastasis using tumour lines of various metastatic ability (Harris et al., 1982) In the in vitro studies R3230AC cells shed significantly large amounts of bound NANA compared to the non-metastatic tumour lines. For the in vivo studies, the level of bound NANA in sera of R3230AC tumour-bearing animals was high. The level of bound NANA in these tumour-bearing animals correlated to the metastatic potential of the R3230AC tumour. However, in the tumour-bearing animals there was no direct correlation between elevated serum bound NANA and the presence of metastasis; both non-metastatic and metastatic tumour-bearing animals had similar serum bound NANA levels. The study with the R3230AC tumour does suggest that NANA shedding is not a phenotypic marker for the presence of metastasis.
An interesting characteristic of the R3230AC tumour is that it metastasizes occasionally. There is a possibility that all R3230AC cells release bound NANA; however the establishment of metastasis does not always occur in all animals due to a host or other cell characteristic(s).
The levels of bound NANA detected in blood may be affected by host factors which can play a role in their rapid removal. Bound NANA in blood could be removed by the reticuloendothelial system (Baldwin & Robins; 1977) or by specific antibodies (Kim, 1979) . Thus one has to be cautious in interpreting in vivo results, such as in the R3230AC tumour model where bound NANA levels were low at early stages of growth. At this stage the host system may have been effective in removing the bound NANA from the blood.
A portion of the bound NANA in tumour serum hydrolysates may be of host origin, however, this has yet to be determined. Various secondary factors such as a1-acid glycoprotein from the liver may be elevated in the blood in response to tumour or more particularly metastasis to liver (Chandrasekaran et al; . In our tumour models there was no metastasis to the liver and direct correlation between rise in serum bound NANA and metastasis. Recently, a report by Huggins et al. (1980) (Sugarbaker, 1979) . Tumour cells have been shown to contain plasminogen activator which is capable of activating the blood proenzyme plasminogen to plasmin (Ramshaw et al., 1982) . The activation of plasmin to proteolytic enzyme near the tumour cell surface may be responsible for cell surface shedding (Unkeless et al., 1979) . Previously we showed that high levels of plasminogen activator were released by 13762 cells, but only low levels were released by TgR cells (Ramshaw et al., 1982 Steck & Nicolson (1983) suggest that the quantitative changes on the cell surface glycoproteins of the 13762NF MAT rather than the qualitative changes are associated with metastatic behaviour.
Further studies will involve characterization of the shed bound NANA carbohydrate components.
